The impact of conventional and high-dose therapy for lymphoma on fertility.
Grigg
Andrew
A
Department of Haematology, Royal Melbourne Hospital, Victoria, Australia. andrew.grigg@mh.org.au
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005298:Fertility / Q000187:drug effects*; D006689:Hodgkin Disease / Q000188:drug therapy; D020249:Hormone Replacement Therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone